Company Quick10K Filing
Generex Biotechnology
S-1 2020-08-20 Public Filing
S-1 2020-06-15 Public Filing
10-Q 2020-04-30 Filed 2020-06-22
S-1 2020-02-18 Public Filing
10-Q 2020-01-31 Filed 2020-03-20
S-1 2019-12-12 Public Filing
10-Q 2019-10-31 Filed 2019-12-16
10-K 2019-07-31 Filed 2019-11-12
10-Q 2019-04-30 Filed 2019-06-19
10-Q 2019-01-31 Filed 2019-03-25
8-K 2020-08-25 Enter Agreement, Exhibits
8-K 2020-08-04 Enter Agreement, Sale of Shares, Shareholder Rights, Exhibits
8-K 2020-07-31 Enter Agreement, Exhibits
8-K 2020-07-13 Other Events, Exhibits
8-K 2020-06-24 Other Events, Exhibits
8-K 2020-06-23
8-K 2020-06-22
8-K 2020-06-19
8-K 2020-06-18
8-K 2020-06-17
8-K 2020-06-16
8-K 2020-06-15
8-K 2020-06-11
8-K 2020-06-10
8-K 2020-06-09
8-K 2020-06-08
8-K 2020-06-02
8-K 2020-05-14 Other Events, Exhibits
8-K 2020-03-12
8-K 2020-03-03
8-K 2020-02-28
8-K 2020-01-27
8-K 2019-11-22
8-K 2019-11-19
8-K 2019-10-29
8-K 2019-10-28
8-K 2019-10-25
8-K 2019-07-11
8-K 2019-05-06
8-K 2019-04-01
8-K 2019-03-29
8-K 2019-03-25
8-K 2019-02-21
8-K 2019-02-15
8-K 2019-02-13
8-K 2019-02-08
8-K 2019-01-25
8-K 2019-01-24
8-K 2019-01-15
8-K 2019-01-07
8-K 2019-01-07

Generex Biotechnology Financials

GNBT Metrics, Comps, Filings

Quarterly | Annual

Valuation ($MM)

Market Cap, Enterprise Value

Balance Sheet ($MM)

Assets, Equity

Income Statement ($MM Quarterly)

Revenue, G Profit, Net Income

Cash Flow ($MM Quarterly)

Ops, Inv, Fin

Comps ($'000 TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
Rebel Group (REBL) 0% 0.0 -1,380% 703 4,933 140 0 -9,708 -9,660 -395
Generex Biotechnology (GNBT) 21% 0.0 -49% 52,240 43,297 1,764 374 -25,717 -18,297 -540
Poverty Dignified (POVD) 0.0 -4,053% 49 3,080 0 0 -2,000 -1,786 -41
Zhong Ya (WLUC) 0.0 0 63 0 0 -562 -562 -0
Weyland Tech (WEYL) 18% 2.2 -24% 11,699 2,218 24,630 4,372 -2,779 -2,702 -5,821
Longbau (LNGB) 4% -1.0 2% 10,660 10,136 4,882 210 165 222 -233
Scandium International Mining (SCY) 0.1 -171% 957 303 0 0 -1,636 -1,634 -219
Aprea Therapeutics (APRE) 8.4 -11% 57,336 9,943 0 0 -6,249 -6,249 -52,334
IntelliSense Solutions (INLL) 0.0 -7,286% 2 273 0 0 -178 -164 -2
Metropolitan Life Insurance (MLIC) 0% -1.8 1% 437,745,000 403,121,000 37,348,000 0 4,559,000 4,960,000 -8,986,000
Zeta Acquisition I (ZETAI) 0.2 -649% 4 324 0 0 -29 -18 -4
Ando Holdings (ANDO) 1.1 -74% 73 160 0 0 -54 -54 -61
Po Yuen Cultural (POYE) 0.0 -1,973% 1 68 0 0 -20 -20 -0
Advanced Biomedical Technologies (ABMT) 0.0 -321% 218 6,589 0 0 -701 -701 -11
Kyto Technology & Life Science (KBPH) 0% 0.8 -12% 2,578 66 15 0 -315 -315 -238
Federal Home Loan Bank of Topeka (FHLBT) 29.6 0% 57,131,130 54,472,808 0 0 132,964 1,095,234 32,380,961
CNL Healthcare Properties II (CHPII) 67% -4.4 68,889,100% 8,277 5,549 -689 1,137 -4,981
Original Source Music (OSMU) 0.0 743,400% 35 0 0 -7 -7 -0
Graham Alternative Investment Fund I (GAIF) -0.0 0% 29,076 1,126 0 0 0 5 -0
JiaLiJia Group (RZZN) 0.0 -1,721% 4 139 0 0 -69 -69 -0

Balance Sheet ($'000)2019-04-302019-07-312019-10-31
Cash1,408298540
Accounts Receivable1,80336155
Inventory250363727
PP&E666640769
Assets54,03649,63652,240
Accounts Payable
Long-Term Debt530447
Liabilities40,23337,88943,297
Stockholders' Equity13,8037,6734,869
Income Statement ($'000)2019-04-302019-07-312019-10-31
Revenue1,093-51722
Cost of Revenue1,265-9134
Gross Profit-172-42588
R&D472286339
SG&A8,6573,8644,787
Tax
Net Income-11,153-5,251-9,313
Cash Flow ($'000)2019-04-302019-07-312019-10-31
Cash Operating-1,516-1,844
Cash Investing3645
Cash Financing3812,041